Vaxcyte Inc
1PCVX
Company Profile
Business description
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Contact
825 Industrial Road
Suite 300
San CarlosCA94070
USAT: +1 650 837-0111
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
414
Stocks News & Analysis
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
stocks
ASX results reaction: WiseTech, Woolies, Sigma and more
A round up of notable stories and reactions as ASX reporting season rolls on.
stocks
WiseTech result disappoints, but the future looks bright
Markets appear underwhelmed by recent sales growth, however, our kingmaker thesis is intact.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,243.00 | 9.00 | 0.10% |
CAC 40 | 7,703.90 | 58.70 | -0.76% |
DAX 40 | 23,902.21 | 137.71 | -0.57% |
Dow JONES (US) | 45,544.88 | 92.02 | -0.20% |
FTSE 100 | 9,187.34 | 29.48 | -0.32% |
HKSE | 25,077.62 | 78.80 | 0.32% |
NASDAQ | 21,455.55 | 249.61 | -1.15% |
Nikkei 225 | 42,718.47 | 110.32 | -0.26% |
NZX 50 Index | 12,930.73 | 27.65 | 0.21% |
S&P 500 | 6,460.26 | 41.60 | -0.64% |
S&P/ASX 200 | 8,973.10 | 4.10 | 0.05% |
SSE Composite Index | 3,857.93 | 14.33 | 0.37% |